Search for a clinical trial
Other search option(s)
14 Result(s)
Recruiting trial
= 
; Ongoing trial
= 
; Terminated trial = 
; Funded by an IRDiRC member = 
; Member of a ERN = 
National clinical trial(s)
GERMANY
Baden-Württemberg
HEIDELBERG
An open-label first-in-human phase 1/2a study to evaluate safety, feasibility and efficacy of multiple dosing with individualised VB10.NEO or VB10.NEO and bempegaldesleukin (NKTR-214) immunotherapy in patients with locally advanced or metastatic Neoplasia
Nationales Centrum für Tumorerkrankungen (NCT)
Nationales Centrum für Tumorerkrankungen (CCC) Heidelberg
UNITED KINGDOM
Lancashire
PRESTON
POUT: A Phase III randomised trial of Peri-Operative chemotherapy versus sUrveillance in upper Tract urothelial cancer
Royal Preston Hospital
Rosemere Cancer Centre
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
An open label, multicenter pasireotide roll over protocol for patients who have completed a previous Novartis sponsored pasireotide study and are judged by the investigator to benefit from continued pasireotide treatment - ES
Institution: Information not provided - ES
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
NETTER-1: A Multicentre, Stratified, Open, Randomized, Comparator-controlled, Parallel-group Phase III Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours - AT
Institution: Information not provided - AT
FRANCE
BOURGOGNE-FRANCHE-COMTE
BESANÇON
EPICentro : Pharmaco-immunological Study of Interferon-alpha and Metronomic Cyclophosphamide Association in Neuroendocrine Tumors (Phase II)
CHU de Besançon - Hôpital Jean Minjoz
Service d'oncologie médicale
FRANCE
ILE-DE-FRANCE
VILLEJUIF
AcSé : Secured Access to Pembrolizumab for Adult Patients With Selected Rare Cancer Types (Phase II)
CLCC Institut Gustave Roussy
Département d'Innovation Thérapeutique et d'Essais Précoces
GERMANY
Bayern
ERLANGEN
EVINEC: Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study - DE
Internistisches Zentrum des Universitätsklinikums Erlangen
Medizinische Klinik 1 - Gastroenterologie, Pneumologie und Endokrinologie
ITALY
EMILIA ROMAGNA
MELDOLA
A Phase II Study on Adjuvant Vaccination With Dendritic Cells Loaded With Autologous Tumor Homogenate in Resected Stage IV Rare Cancers: Head&Neck (H&N), Neuroendocrine Tumors (NET) and Soft Tissue Sarcoma (STS)
IRST - Istituto Scientifico Romagnolo per lo studio e la cura dei Tumori
Dipartimento di Oncologia ed ematologia clinica e sperimentale
ITALY
EMILIA ROMAGNA
MELDOLA
LUTHREE - Randomized Phase II Trial in sstr2 Positive Tumors to Optimize the Interval Between Cycles of PRRT With 177lu-dotatate Study
IRST - Istituto Scientifico Romagnolo per lo studio e la cura dei Tumori
UO Medicina Nucleare
ITALY
PUGLIA
SAN GIOVANNI ROTONDO
Bevacizumab in association with slow-relapsing Octreotide and Capecitabine in patients with well-differentiated neuroendocrine neoplasia and in advanced phase (Phase II)
Fondazione IRCCS Ospedale Casa Sollievo della Sofferenza
U.O. di Oncologia
NETHERLANDS
Noord-Holland
AMSTERDAM
The Drug Rediscovery Protocol (DRUP trial): A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile (Phase II)
Het Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis
Afdeling Maag-Darm-Leveroncologie
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
An Open-Label Phase 2 Study of Surufatinib in Patients with Neuroendocrine Tumours in Europe - ES
Institution: Information not provided - ES
BELGIUM
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
STEP: Sorafenib Long Term Extension Program - BE
Cliniques universitaires Saint-Luc - UCLouvain
Pneumologie_Oncologie thoracique
ITALY
LAZIO
ROMA